SCHEMBL599554

SCHEMBL599554

COC(=O)C(C)=CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
HCAR2 Q8TDS4 2/20 0.39
HTT P42858 2/20 0.35
EGLN1 Q9GZT9 1/20 0.34
KDM4E B2RXH2 5/20 0.34
MAPT P10636 2/20 0.34
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
ALOX15 P16050 1/20 0.32
RECQL P46063 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ATM Q13315 1/20 0.32
TSHR P16473 1/20 0.32
PARP1 P09874 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL599552 1.00 ALDH1A1 (0.42) ALDH1A1HCAR2HTTEGLN1KDM4E
SCHEMBL7771328 1.00 ALDH1A1 (0.42) ALDH1A1HCAR2HTTEGLN1KDM4E
Fumaric Acid SCHEMBL29989236 0.93 HCAR2 (0.50) ALDH1A1HCAR2HTTEGLN1KDM4E
Acetic Acid SCHEMBL27317270 0.82 ALDH1A1 (0.40) ALDH1A1HCAR2EGLN1KDM4EMAPT
SCHEMBL623254 0.81 HTT (0.36) ALDH1A1HTTKDM4EMAPTCYP1A2
SCHEMBL7037263 0.81 ALDH1A1 (0.43) ALDH1A1HCAR2EGLN1KDM4EMAPT
SCHEMBL28023754 0.81 ALDH1A1 (0.43) ALDH1A1HCAR2EGLN1KDM4EMAPT
SCHEMBL14749991 0.81 ALDH1A1 (0.43) ALDH1A1HCAR2EGLN1KDM4EMAPT
SCHEMBL20025 0.81 HTT (0.36) ALDH1A1HTTKDM4EMAPTCYP1A2
SCHEMBL12065716 0.81 ALDH1A1 (0.43) ALDH1A1HCAR2EGLN1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210161851-A1 COMBINATION THERAPY OF LYMPHOMA DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2021-06-03 US claimed
EP-2900815-B1 METHODS AND TOOLS FOR IDENTIFICATION OF RSK/MSK KINASE INHIBITORS UNIV AARHUS (DK) 2017-06-21 EP claimed
EP-0601754-B1 Vinylidene fluoride copolymer, and binder composition containing the copolymer for non-aqueous solvent type secondary battery KUREHA CHEMICAL IND CO LTD (JP) 1998-01-21 EP claimed
US-5534341-A LOFTED NON-WOVEN MATERIAL; FIREPROOFING UNILEVER PATENT HOLDINGS BV (NL) 1996-07-09 US claimed
US-5415958-A Monoester of unsaturated diacid copolymers KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1995-05-16 US claimed
EP-0601754-A1 Vinylidene fluoride copolymer, and binder composition containing the copolymer for non-aqueous solvent type secondary battery KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-06-15 EP claimed
EP-0269274-B1 Process for the preparation of thermoplastic elastomer compositions MITSUI PETROCHEMICAL IND (JP) 1993-12-15 EP claimed
EP-0266982-A2 Laminated and molded article prepared therefrom MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-05-11 EP claimed
JP-11130821-A None JP disclosed
JP-6172452-A None JP disclosed
US-12609414-B2 Non-aqueous secondary battery TEIJIN LIMITED (JP) 2026-04-21 US disclosed
EP-4414420-B1 VINYLIDENE FLUORIDE POLYMER SOLUTION KUREHA CORP (JP) 2026-04-08 EP disclosed
US-12594259-B2 Treatment regimen for the treatment of neurological diseases or conditions ACCURE THERAPEUTICS, S.L. (ES) 2026-04-07 US disclosed
US-20260076940-A1 TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS ACCURE THERAPEUTICS, S.L. (ES) 2026-03-19 US disclosed
EP-0226055-A1 Carboxylated phenylene ether resins GE CHEMICALS, INC. (US) 1987-06-24 EP disclosed
EP-0219548-A1 POLYOLEFIN FOAM COMPOSITIONS HAVING IMPROVED DIMENSIONAL STABILITY UTILIZING CERTAIN UNSATURATED NITROGEN-CONTAINING COMPOUNDS ANDPROCESS FOR MAKING SAME. DOW CHEMICAL CO (US) 1987-04-29 EP disclosed
WO-1986007076-A1 POLYOLEFIN FOAM COMPOSITIONS HAVING IMPROVED DIMENSIONAL STABILITY UTILIZING CERTAIN UNSATURATED NITROGEN-CONTAINING COMPOUNDS ANDPROCESS FOR MAKING SAME THE DOW CHEMICAL COMPANY (US) 1986-12-04 WO disclosed
US-4203996-A Synthetic cephalotaxine esters having antileukemic P388 activity THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1980-05-20 US disclosed
US-4152333-A ALKALOIDS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1979-05-01 US disclosed
US-4013524-A Electrolytic carboxylation and dimerization of olefins MONSANTO COMPANY (US) 1977-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210161851-A1 COMBINATION THERAPY OF LYMPHOMA IKBKB, NFKBIA, BCL3 ALDH1A1 1296/4885HCAR2 973/4885HTT 4426/4885
US-12594259-B2 Treatment regimen for the treatment of neurological diseases or conditions PMP22, SMN1; SMN2, MYT1 ALDH1A1 622/4885HCAR2 2345/4885HTT 94/4885
US-12609414-B2 Non-aqueous secondary battery SLC9A2, SLC9A1, TAF9 ALDH1A1 3694/4885HCAR2 4842/4885HTT 3082/4885
US-20260076940-A1 TREATMENT REGIMEN FOR THE TREATMENT OF NEUROLOGICAL DISEASES OR CONDITIONS AQP4, SCN10A, PMP22 ALDH1A1 3076/4885HCAR2 3652/4885HTT 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.